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Ranolazine reduces symptoms of palpitations and documented
arrhythmias in patients with ischemic heart disease — The
RYPPLE randomized cross-over trial
Francesco Pelliccia, Giuseppe Campolongo, Rosalba Massaro,
Vincenzo Pasceri, Cesare Greco, Carlo Gaudio
Department of Cardiology, University of Rome “La Sapienza”, Italy
Background: Ranolazine decreases the frequency of arrhythmias
during the acute phases of ischemic heart disease (IHD), but it
remains unknown if it has similar effects in the chronic phase of the
disease. We performed a prospective, randomized, cross-over pilot
trial to test the hypothesis that chronic treatment with ranolazine
can reduce the incidence of documented arrhythmias and the related
symptoms of palpitation in stable patients with IHD.
Methods: We randomized 105 patients with stable IHD and
symptoms of angina and palpitations already on therapy with beta-
blockers and/or calcium antagonists to ranolazine (750 mg bid,
N = 53) or placebo (N = 52) for 30 days (until T-1). After a wash-
out period to avoid any carryover effect, cross-over was
performed,and patients were switched to the other drug which was
continued for 30 days (until T-2). All patients underwent symptom-
limited exercise stress testing and 48-hour ECG Holter monitoring at
T1 and T2. During the study period, patients were told to use a
OmronN® portable ECG monitor HCG-801 device in case of
symptoms of palpitations.
Results: Ranolazine reduced the number of anginal episodes more
commonly than placebo (5 ± 8 episodes/30 days vs. 21 ± 24 epi-
sodes/30 day, p = 0.001) and increased exercise durations at 1 mm
ST-segment depression (514 ± 211 s vs. 402 ± 287 s, p = 0.025)
and at onset of angina (614 ± 199 s vs. 519 ± 151 s, p = 0.007) at
stress testing.
These effects were coupled by signiﬁcant decreases with
ranolazine as compared with placebo treatment periods in the
occurrence of frequent (N1000 beats) supraventricular arrhythmias
(33% vs 52%, p = 0.01) and complex ventricular arrhythmias (17% vs
30%, p = 0.045). Complete resolution of symptoms of palpitations
was signiﬁcantly more common with ranolazine than placebo (31/53
vs 16/52 patients, p = 0.008). Also, portable ECG recordings showed
that arrhythmias were less common during ranolazine vs. placebo,
with signiﬁcant decreases in number (7 ± 10 episodes/30 days vs.
23 ± 29 episodes/30 day, p = 0.001) and duration (10 ± 18 min/
30 days vs. 19 ± 21 min/30 day, p = 0.021) of symptomatic arrhyth-
mic episodes. No severe side effects were recorded during the trial
period.
Conclusion: The antianginal and antiischemic properties of ranolazine
are paralleled by signiﬁcant decreases in the occurrence of both
arrhythmias and the related symptoms of palpitations in stable patients
with IHD. (ClinicalTrials.gov identiﬁer: NCT01495520).
doi:10.1016/j.ijcme.2015.05.016
Local delivery of thrombolytics before thrombectomy in patients
with ST-elevation myocardial infarction undergoing primary
percutaneous coronary intervention — The DISSOLUTION
randomized trial
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Background: Prompt reperfusion with percutaneous coronary
intervention (PCI) in ST-elevation myocardial infarction (STEMI)
improves clinical outcomes through salvage of myocardial tissue.
Although use of thrombus aspiration with PCI can improve epicardial
ﬂow and myocardial perfusion, several unmet needs remain. The
purpose of this trial was to evaluate the hypothesis that local
delivery of low-dose thrombolytics can enhance the efﬁcacy of
thrombus aspiration in STEMI patients undergoing primary PCI.
Methods: A total of 102 patients with STEMI and angiographic
evidence of totally occlusive thrombosis in the culprit artery were
randomly assigned to receive local bolus of 200,000 units urokinase
(N = 51) or saline solution (N = 51) followed by manual aspiration
thrombectomy (Pronto™, Vascular Solutions, Inc., Minneapolis,
Minnesota) and PCI. Both groups received abciximab (i.v. bo-
lus + 12-h infusion). End points included ﬁnal thrombolysis in
myocardial infarction (TIMI) ﬂow grade, frame count, and thrombus
grade N 2, myocardial blush grade (MBG), 60-min ST-segment
resolution (STR) N 70%, and 6-month clinical outcomes. All patients
had echocardiography at 6-month and left ventricular ejection
fraction (EF) and wall motion score (WMS) were obtained.
Results: Baseline clinical and angiographic characteristics of both
groups were similar. Local urokinase was associated with post-PCI
evidence of higher TIMI ﬂow grade 3 (96% vs. 68%; p = 0.027), lower
TIMI frame count (18 ± 11 vs. 25 ± 13; p = 0.045) and fewer TIMI
thrombus grade N 2 (20% vs. 52%; p = 0.039). Histopathologic
evaluation performed in 11 Gr. A and 11 Gr. B patients showed that
aspirated thrombi after urokinase were smaller, softer and less
organized than after saline. Post-PCI myocardial perfusion was
slightly increased with urokinase (MBG 2/3: 88% vs. 64%;
p = 0.09), with signiﬁcantly more patients showing STR N 70% (80%
vs 56%, p = 0.001). No differences between the two groups were
subsequently seen in clinical outcomes and EF, whereas 6-month
WMS was signiﬁcantly lower in patients receiving local urokinase
than saline (1.21 ± 0.29 vs 1.45 ± 0.32, p = 0.008).
Conclusion: Local delivery of low-dose thrombolytics before
thrombectomy in STEMI patients undergoing primary PCI is associ-
ated with improved coronary ﬂow, myocardial perfusion, and 6-
month regional myocardial function. Delivery of low-dose thrombo-
lytic agents directly to the site of thrombus might be an effective
strategy to enhance efﬁcacy of thrombus aspiration in primary PCI.
(ClinicalTrials.gov identiﬁer: NCT01568931).
doi:10.1016/j.ijcme.2015.05.017
Pharmacodynamic effects of atorvastatin vs. rosuvastatin in
coronary artery disease patients with normal platelet reactivity
while on dual antiplatelet therapy — The PEARL randomized
cross-over study
Francesco Pelliccia, Giuseppe Marazzi, Vincenzo Pasceri, Marina
Polacco, Luigi Mattioli, Cesare Greco, Carlo Gaudio
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Background: Levels of platelet reactivity in patients on dual
antiplatelet therapy (DAPT) can potentially be inﬂuenced by
concomitant treatment with statins that inhibit the CYP3A4 system
involved in the activation of clopidogrel. Recent studies have shown
that a high platelet reactivity during co-administration of clopidogrel
and a CYP3A4-metabolized statin (i.e. atorvastatin) can be lowered
by switching to a non-CYP3A4-metabolized statin (i.e. rosuvastatin).
Aim of this study was to verify if atorvastatin and rosuvastatin have
different pharmacodynamic effects also when they are given to
patients with coronary artery disease (CAD) with baseline normal
platelet reactivity while on DAPT.
Methods: A total of 100 stable CAD patients receiving DPAT
(clopidogrel 75 mg plus aspirin 100 mg) who had evidence of normal
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platelet reactivity after a 1-week statin wash-out period entered the
PEARL trial. Patientswere randomly assigned to atorvastatin (20 mg day,
N= 50) or rosuvastatin (10 mg day, N= 50) for 30 days. After another
1-week wash-out period to avoid any carryover effect, cross-over was
performed, and patients were switched to the other drug which was
continued for 30 days. Platelet reactivity (expressed as P2Y(12) reaction
units (PRU) by the point-of-care VerifyNow assay [Accumetrics, San
Diego, California]) was measured before and at the end of each 30-day
treatment period. High platelet reactivity after clopidogrel was deﬁned
as a PRU value N 208.
Results: After the 30-day treatment with atorvastatin, platelet
reactivity did not signiﬁcantly change as compared with baseline,
pre-treatment evaluation (119 ± 66 vs 136 ± 59 PRU, NS), with 2
patients only showing a PRU N 208. Similarly, after 30-day treatment
with rosuvastatin, platelet reactivity was unchanged as compared
with baseline (135 ± 46 vs 128 ± 62 PRU, NS), with PRU N 208
occurring in 3 patients.
Conclusion: Atorvastatin does not negatively affect DAPT as com-
pared with rosuvastatin when is given to stable CAD patients with
baseline normal platelet reactivity while on DAPT. (ClinicalTrials.gov
Identiﬁer: NCT01567774).
doi:10.1016/j.ijcme.2015.05.018
Pharmacodynamic comparison of pitavastatin versus atorvastatin
on platelet reactivity in patients with coronary artery disease
treated with dual antiplatelet therapy — The PORTO Trial
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Background: Levels of platelet reactivity in patients on dual
antiplatelet therapy (DAPT) can be inﬂuenced by concomitant
treatment with medications (i.e. statins) that inhibit the CYP3A4
system involved in the activation of clopidogrel. Atorvastatin and
simvastatin are metabolized by CYP3A4, while pitavastatin is mostly
excreted unchanged in bile and undergoes minimal biotransforma-
tion through the cytochrome P450 system. The primary objective of
this study was to compare the pharmacodynamic effects of a
CYP3A4-metabolized statin (atorvastatin) versus a non-CYP3A4-
metabolized statin (pitavastatin) in patients with coronary artery
disease (CAD) treated with DAPT.
Methods: A total of 102 CAD patients receiving DPAT (clopidogrel
75 mg plus aspirin 100 mg) after percutaneous coronary interven-
tion entered the PORTO trial. After a 1-week statin wash-out period,
patients were randomly assigned to atorvastatin (20 mg day,
N = 51) or pitavastatin (4 mg day, N = 51) for 30 days. After
another 1-week wash-out period to avoid any carryover effect,
cross-over was performed, and patients were switched to the other
drug which was continued for 30 days. Platelet reactivity (expressed
as P2Y(12) reaction units (PRU) by the point-of-care VerifyNow
assay [Accumetrics, San Diego, California]) was measured before and
at the end of each 30-day treatment period. High platelet reactivity
after clopidogrel was deﬁned as a PRU value N 208.
Results: After the 30-day treatment period with atorvastatin,
platelet reactivity was signiﬁcantly higher as compared with pre-
treatment values (212 ± 96 vs 166 ± 79 PRU, p = 0.010), with a
more common occurrence of patients showing a PRU N 208 (57% vs.
35%, p = 0.047). Conversely, after the 30-day treatment period with
pitavastatin, platelet reactivity was unchanged as compared with
pre-treatment values (178 ± 81 vs 189 ± 73 PRU, NS), with no
difference in the frequency of patients showing a PRU N 208 before
and after treatment (41% vs. 37%, NS).
Conclusion: Pitavastatin, a non-CYP3A4-metabolized statin, does
not negatively affect DAPT as compared with atorvastatin in CAD
patients on DAPT. (ClinicalTrials.gov Identiﬁer: NCT01648829).
doi:10.1016/j.ijcme.2015.05.019
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intervention to improve lipid proﬁle in the real world clinical
practice in European countries — The PIN (Portugal Italy
Nutraceutical) Study
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Introduction: Cardiovascular prevention include a class I indication to
statins in addition to non-pharmacologic intervention and prevention
strategies in patients deemed to be ‘high risk’ according to current
scientiﬁc guidelines. In the real world, however, statin treatment is often
discontinued due to side effects. In addition, statins are not indicated in
those subjects deemed to be ‘low risk’, inwhomonly non-pharmacologic
intervention and prevention strategies are currently prescribed. Along
with non-pharmacologic intervention and prevention strategies, newer
approaches to reduce cholesterol blood levels currently include
nutraceuticals, which are compounds derived from foods with choles-
terol lowering actions. The primary objective of this study is twofold:
First, to prospectively compare in the real world clinical practice the
efﬁcacy and tolerability of non-pharmacologic intervention vs. the
combination of non-pharmacologic intervention with a nutraceutical-
based protocol in patients inwhom statin treatment is not tolerated or is
not indicated. Second, to evaluate gender and race/ethnic differences in
the hypolipidemic effects of a nutraceutical-based protocol among
European countries.
Methods: Class I indication to receive statin treatment but previous
(b12 months) withdrawn of a statin due to side effects and unwilling to
receive treatment with an alternative statin. Class I indication to receive
non-pharmacologic intervention and prevention strategies because of
hyperlipidemia with ‘low risk’ classiﬁcation.
Patients will be assigned at the discretion of their own general
practitioner to receive for 1 year either non-pharmacologic inter-
vention and prevention strategies or non-pharmacologic interven-
tion and prevention strategies associated with a commercially
available nutraceutical combined pill (1 capsule/day containing red
yeast rice 200 mg, policosanol 10 mg, and berberine 500 mg).
Primary outcome included reasons for treatment discontinuation
use and secondary outcomes included plasma lipids levels.
Results: At entry, 51 patients were randomized to ezetimibe and 50
to placebo. Baseline clinical features and lipid proﬁles were similar
between groups. During the 1-year trial, 5 patients of the nutraceutical-
group stopped the pill due to myalgia whereas in the ezetimibe group 4
patients had gastrointestinal intolerance and 3 had fatigue and dizziness
(NS). At 1-year evaluation, levels of triglyceride, creatine kinase or liver
enzymes were similar between groups. Conversely, total cholesterol
level (205 ± 31 vs 241 ± 41 mg/dl, p = 0.001) and LDL cholesterol
(105 ± 31 vs 131 ± 41 mg/dl, p = 0.001) were signiﬁcantly lower in
the nutraceutical-group than in the ezetimibe-group.
Conclusions: A combination of nutraceuticals with lipid-lowering
biological activity can signiﬁcantly decrease cholesterol levels
without causing clinical or metabolic side effects and is more
effective than ezetimibe 10 mg/day in statin-intolerant patients
treated with PCI. (ClinicalTrials.gov Identiﬁer: NCT01649986).
doi:10.1016/j.ijcme.2015.05.020
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